about
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphataseThe R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma KinaseIdentification of cancer genes by mutational profiling of tumor genomesEffect of cellular quiescence on the success of targeted CML therapyCombination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemiaOptimizing combination therapies with existing and future CML drugsA computational approach to finding novel targets for existing drugsCombined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signaturesApplication of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaA target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLFluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase FunctionNon-antioxidant properties of α-tocopherol reduce the anticancer activity of several protein kinase inhibitors in vitroProteomics and mass spectrometry for cancer biomarker discoveryc-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in SolutionIdentification of Dual Natural Inhibitors for Chronic Myeloid Leukemia by Virtual Screening, Molecular Dynamics Simulation and ADMET Analysis.Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitorsBioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity.Epidemiological and molecular mechanisms aspects linking obesity and cancer.JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo.The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell linesUsing LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.Targeting PTPs with small molecule inhibitors in cancer treatmentIn vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells.Cancer and the tumor microenvironment: a review of an essential relationship.Drug resistance in cancer: principles of emergence and prevention.Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor.Cancer driver mutations in protein kinase genesSequence survey of receptor tyrosine kinases reveals mutations in glioblastomasThe colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines.Recent advances in the understanding of mastocytosis: the role of KIT mutations.The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.A robust approach to enhance tumor-selective accumulation of nanoparticles.Cure therapeutics and strategic prevention: raising the bar for mental health research.In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesisAnaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.Predicting new indications for approved drugs using a proteochemometric method.Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemiaLimited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease
P2860
Q24294831-DCD27E88-93D3-42DB-95BD-6E1869C938D5Q27671787-657DDFA2-B7A8-442F-B094-1E5CA0842E15Q28239452-80F9375D-93A3-4A1D-9979-0DD9C64F0EB1Q28469312-118D5295-B60B-417B-8E0A-9952E4B8CE54Q28474737-DF70A558-22D2-43C8-A061-E4CE26476E60Q28475255-9601DD94-9CB4-45E3-B541-2EE31B767F11Q28476770-30D98A12-4A23-479D-A9BF-E2FB2BBC2581Q28484238-1A64654E-2566-4FC4-8285-1FC1AEEB7EE5Q28534259-F662DE40-7E59-44F9-A11A-B6708DDE5193Q28534337-89F0FDD9-C296-4A0E-B75D-CFF95AFD1B9AQ28546849-3FFDF4A1-464C-4E0E-92FF-9874BFF54AEBQ28730066-D6FD365A-E10C-4299-BAC6-DCF524BEBFA9Q28766969-39AD9825-468C-4014-9118-FF5D8E405075Q30008916-A5A8B220-4B87-4E0F-AF8B-AEAD18C46440Q30009113-261A533A-EC7D-4EFF-985E-79526FD37D66Q30009947-1D15D138-98A2-472F-A8CB-4FDD473406BAQ30370399-281E3854-2E6A-47DB-9A91-FE260717B01EQ30377470-62A51B0F-447F-4CA7-AC6A-C4F3E54DF4E0Q33341856-697954BA-0ECD-4BCF-A747-E4ED7B15443FQ33385649-8557A9A9-8A34-48B1-8C11-0491E172A224Q33409151-24B3ACD6-D96A-45BC-BA2D-31D895613484Q33491567-AC71AA5C-506C-42D9-833A-F1E336507E30Q33554884-A3A96DC0-D23D-4B34-BAAB-AD9BD8AEDFEDQ33651783-7F961064-A5D3-4E4D-BF3F-C078A54D217CQ33806357-64655451-7D29-4A9B-911E-05DC01F813E5Q33892278-8CBFACFD-354C-4597-B7AA-30A3F15E61EAQ33926815-A76FFE30-53E3-41BC-B1BF-414BC63EDC52Q34002709-95688964-0606-474E-BD4A-9FD327B77E22Q34063705-1C94E73B-58FE-4E30-A515-30072902203EQ34077902-BAAEA3BD-4DF6-41F0-AE7D-B82EDB3DB2B1Q34635424-DDE535B2-B7BF-4C25-96F7-E610B3A31E62Q34748167-9F15D79B-F1DC-44AF-AF87-C5E45F69F86BQ34754720-9CCD5DBF-228C-428B-B956-9C73F738F822Q35062074-791EB1F0-9388-4315-B7E3-B2364133853FQ35812209-74CF6F7F-D140-451B-B93D-D2D50CD148A2Q36007575-E8E69939-6A7B-4342-9208-E8664B06AC1EQ36158713-FC206999-9A7A-4E4E-8ED0-C656C5941479Q36165369-246940D7-6090-48C9-A5A7-F2CC0C174746Q36174305-9CA4EC43-5181-4254-A889-5E5B26A695BEQ36220062-62F8200A-1D16-4255-910A-C19C5AF419C5
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Imatinib as a paradigm of targeted therapies.
@ast
Imatinib as a paradigm of targeted therapies.
@en
type
label
Imatinib as a paradigm of targeted therapies.
@ast
Imatinib as a paradigm of targeted therapies.
@en
prefLabel
Imatinib as a paradigm of targeted therapies.
@ast
Imatinib as a paradigm of targeted therapies.
@en
P1476
Imatinib as a paradigm of targeted therapies.
@en
P356
10.1016/S0065-230X(04)91001-9
P577
2004-01-01T00:00:00Z